A new study published in the Journal of Climate reveals how surface warming in Antarctica, particularly over the Antarctic Peninsula, is significantly altering the stability of the lowest layers of ...

Experts have warned that extensive storm damage caused to one of South Devon's most iconic routes is likely to become more frequent as global sea levels rise and the impacts of extreme wave events ...

Artificial intelligence has entered a phase that feels both inevitable and strangely precarious. The hype is unmistakable. So is the sense that we are still early — too early — for the broader ...

As AI floods the SOC, security teams are discovering that smarter data architecture may matter more than smarter algorithms.

Weather data from the Pakistan Meteorological Department between 1981 and 2025 shows a noteworthy shift in Islamabad's climate profile.

Current state of AI initiatives; organizations have spent billions of dollars on AI initiatives. As per published reports, only 5% of the initiatives are delivering value, and the payback period for ...

Early 2026 has brought renewed scrutiny to how Earth-observing satellites register extreme ocean events. Widely circulated ...

Arista has outmaneuvered competitors while focused on high-performance data center and cloud networks. But as it eyes a greater role in enterprise campus and branch infrastructure, it needs to ...

Sarah Ference, CPA, an author of the JofA’s Professional Liability Spotlight column, returns to the JofA podcast to discuss recent column topics and the advice CPAs can gain from them. In particular, ...

Hello, and welcome to Wave Life Sciences Positive Interim Clinical Data from INLIGHT Trial of WVE-007 and Obesity call. [Operator Instructions]. Also, as a reminder, this conference is being recorded ...

Wave Life Sciences Ltd. (NASDAQ: WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE ...

(RTTNews) - Wave Life Sciences Ltd. (WVE), an RNA medicines-focused clinical-stage biotechnology firm, is set to announce interim data from its ongoing Phase 1 clinical trial evaluating WVE-007, an ...